Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer.

Song KH, Trudeau T, Kar A, Borden MA, Gutierrez-Hartmann A.

Nanotheranostics. 2019 May 13;3(2):212-222. doi: 10.7150/ntno.31827. eCollection 2019.

2.

Pituitary somatolactotropes evade an oncogenic response to Ras.

Roof AK, Trudeau T, Gutierrez-Hartmann A.

Mol Cell Endocrinol. 2018 Nov 15;476:165-172. doi: 10.1016/j.mce.2018.05.006. Epub 2018 May 9.

3.

The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.

Roof AK, Jirawatnotai S, Trudeau T, Kuzyk C, Wierman ME, Kiyokawa H, Gutierrez-Hartmann A.

Endocrinology. 2018 Jun 1;159(6):2421-2434. doi: 10.1210/en.2017-03135.

4.

ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells.

Kar A, Liu B, Gutierrez-Hartmann A.

Anticancer Res. 2017 Dec;37(12):6583-6591.

5.

ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells.

Kar A, Gutierrez-Hartmann A.

Oncotarget. 2017 Jun 27;8(41):69622-69640. doi: 10.18632/oncotarget.18710. eCollection 2017 Sep 19.

6.

Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific.

Roof AK, Gutierrez-Hartmann A.

Mol Cell Endocrinol. 2018 Mar 5;463:87-96. doi: 10.1016/j.mce.2017.04.019. Epub 2017 Apr 23. Review.

PMID:
28445712
7.

ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.

Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM, Mok SC.

Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.

8.

High Efficiency Molecular Delivery with Sequential Low-Energy Sonoporation Bursts.

Song KH, Fan AC, Brlansky JT, Trudeau T, Gutierrez-Hartmann A, Calvisi ML, Borden MA.

Theranostics. 2015 Oct 18;5(12):1419-27. doi: 10.7150/thno.13033. eCollection 2015.

9.

Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.

Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, Rajpurkar M, Jones K, Gowan K, Balduini C, Pecci A, Gnan C, De Rocco D, Doubek M, Li L, Lu L, Leung R, Landolt-Marticorena C, Hunger S, Heller P, Gutierrez-Hartmann A, Xiayuan L, Pluthero FG, Rowley JW, Weyrich AS, Kahr WHA, Porter CC, Di Paola J.

Nat Genet. 2015 May;47(5):535-538. doi: 10.1038/ng.3253. Epub 2015 Mar 25.

10.

Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis.

Booth AK, Gutierrez-Hartmann A.

Adv Exp Med Biol. 2015;846:37-59. doi: 10.1007/978-3-319-12114-7_2. Review.

PMID:
25472533
11.

Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.

Booth A, Trudeau T, Gomez C, Lucia MS, Gutierrez-Hartmann A.

Mol Endocrinol. 2014 Dec;28(12):1999-2011. doi: 10.1210/me.2014-1168.

12.

Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Kar A, Gutierrez-Hartmann A.

Crit Rev Biochem Mol Biol. 2013 Nov-Dec;48(6):522-43. doi: 10.3109/10409238.2013.838202. Epub 2013 Sep 25. Review.

13.

Control of MicroRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors.

Kern HB, Niemeyer BF, Parrish JK, Kerr CA, Yaghi NK, Prescott JD, Gutierrez-Hartmann A, Jedlicka P.

DNA Cell Biol. 2012 Aug;31(8):1403-11. doi: 10.1089/dna.2011.1469. Epub 2012 May 3.

14.

CEBPD suppresses prolactin expression and prolactinoma cell proliferation.

Tong Y, Zhou J, Mizutani J, Fukuoka H, Ren SG, Gutierrez-Hartmann A, Koeffler HP, Melmed S.

Mol Endocrinol. 2011 Nov;25(11):1880-91. doi: 10.1210/me.2011-1075. Epub 2011 Oct 6.

15.

Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism.

Prescott JD, Poczobutt JM, Tentler JJ, Walker DM, Gutierrez-Hartmann A.

Mol Cancer. 2011 Aug 28;10:103. doi: 10.1186/1476-4598-10-103.

16.

Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression.

McConnell BV, Koto K, Gutierrez-Hartmann A.

Mol Cancer. 2011 Jun 18;10:75. doi: 10.1186/1476-4598-10-75.

17.

MicroRNAs regulate pituitary development, and microRNA 26b specifically targets lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor 1 (Pit-1) expression.

Zhang Z, Florez S, Gutierrez-Hartmann A, Martin JF, Amendt BA.

J Biol Chem. 2010 Nov 5;285(45):34718-28. doi: 10.1074/jbc.M110.126441. Epub 2010 Aug 31.

18.

Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells.

Poczobutt JM, Tentler J, Lu X, Schedin PJ, Gutierrez-Hartmann A.

BMC Cancer. 2010 Jul 16;10:373. doi: 10.1186/1471-2407-10-373.

19.

A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter.

Jean A, Gutierrez-Hartmann A, Duval DL.

Mol Endocrinol. 2010 Jan;24(1):91-103. doi: 10.1210/me.2009-0279. Epub 2009 Nov 3.

20.

The 26-amino acid beta-motif of the Pit-1beta transcription factor is a dominant and independent repressor domain.

Jonsen MD, Duval DL, Gutierrez-Hartmann A.

Mol Endocrinol. 2009 Sep;23(9):1371-84. doi: 10.1210/me.2008-0137. Epub 2009 Jun 25.

21.

The Ets dominant repressor En/Erm enhances intestinal epithelial tumorigenesis in ApcMin mice.

Jedlicka P, Sui X, Gutierrez-Hartmann A.

BMC Cancer. 2009 Jun 22;9:197. doi: 10.1186/1471-2407-9-197.

22.

Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.

Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR.

Thyroid. 2009 Aug;19(8):825-35. doi: 10.1089/thy.2008.0362.

23.

Ets transcription factors control epithelial maturation and transit and crypt-villus morphogenesis in the mammalian intestine.

Jedlicka P, Sui X, Sussel L, Gutierrez-Hartmann A.

Am J Pathol. 2009 Apr;174(4):1280-90. doi: 10.2353/ajpath.2009.080409. Epub 2009 Mar 5.

24.

Ets transcription factors in intestinal morphogenesis, homeostasis and disease.

Jedlicka P, Gutierrez-Hartmann A.

Histol Histopathol. 2008 Nov;23(11):1417-24. doi: 10.14670/HH-23.1417. Review.

25.

ETS transcription factors in endocrine systems.

Gutierrez-Hartmann A, Duval DL, Bradford AP.

Trends Endocrinol Metab. 2007 May-Jun;18(4):150-8. Epub 2007 Mar 26. Review.

PMID:
17387021
26.

Differential utilization of transcription activation subdomains by distinct coactivators regulates Pit-1 basal and Ras responsiveness.

Duval DL, Jonsen MD, Diamond SE, Murapa P, Jean A, Gutierrez-Hartmann A.

Mol Endocrinol. 2007 Jan;21(1):172-85. Epub 2006 Oct 4.

PMID:
17021049
27.

Pit-1beta reduces transcription and CREB-binding protein recruitment in a DNA context-dependent manner.

Ferry AL, Locasto DM, Meszaros LB, Bailey JC, Jonsen MD, Brodsky K, Hoon CJ, Gutierrez-Hartmann A, Diamond SE.

J Endocrinol. 2005 Apr;185(1):173-85.

PMID:
15817838
28.

Structural and functional analysis of the differential effects of c-Jun and v-Jun on prolactin gene expression.

Farrow KN, Bradford AP, Tentler JJ, Gutierrez-Hartmann A.

Mol Endocrinol. 2004 Oct;18(10):2479-90. Epub 2004 Jul 1.

PMID:
15231872
29.

The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism.

Prescott JD, Koto KS, Singh M, Gutierrez-Hartmann A.

Mol Cell Biol. 2004 Jun;24(12):5548-64.

30.

Transcriptional control of the cell cycle in mammary gland development and tumorigenesis.

Coletta RD, Jedlicka P, Gutierrez-Hartmann A, Ford HL.

J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):39-53. Review.

PMID:
15082917
31.

ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells.

Schedin PJ, Eckel-Mahan KL, McDaniel SM, Prescott JD, Brodsky KS, Tentler JJ, Gutierrez-Hartmann A.

Oncogene. 2004 Mar 4;23(9):1766-79.

PMID:
14767472
32.
33.

The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression.

Eckel KL, Tentler JJ, Cappetta GJ, Diamond SE, Gutierrez-Hartmann A.

DNA Cell Biol. 2003 Feb;22(2):79-94.

PMID:
12713734
34.

Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells.

Tentler JJ, Bradford AP, Schweppe RE, Gutierrez-Hartmann A.

Endocrine. 2003 Feb-Mar;20(1-2):3-12.

PMID:
12668863
35.

Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter.

Schweppe RE, Melton AA, Brodsky KS, Aveline LD, Resing KA, Ahn NG, Gutierrez-Hartmann A.

J Biol Chem. 2003 May 9;278(19):16863-72. Epub 2003 Mar 4.

37.

Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphorylation regulates PIT-1/ETS-1 binding.

Augustijn KD, Duval DL, Wechselberger R, Kaptein R, Gutierrez-Hartmann A, van der Vliet PC.

Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12657-62. Epub 2002 Sep 19.

38.

PRL-releasing peptide stimulation of PRL gene transcription--enter AKT.

Duval DL, Gutierrez-Hartmann A.

Endocrinology. 2002 Jan;143(1):11-2. Review. No abstract available.

PMID:
11751585
39.

LZ-FYVE: a novel developmental stage-specific leucine zipper, FYVE-finger protein.

Dunkelberg JC, Gutierrez-Hartmann A.

DNA Cell Biol. 2001 Jul;20(7):403-12.

PMID:
11506704
40.

Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter.

Schweppe RE, Gutierrez-Hartmann A.

Nucleic Acids Res. 2001 Mar 1;29(5):1251-60.

41.
42.

The Pit-1 homeodomain and beta-domain interact with Ets-1 and modulate synergistic activation of the rat prolactin promoter.

Bradford AP, Brodsky KS, Diamond SE, Kuhn LC, Liu Y, Gutierrez-Hartmann A.

J Biol Chem. 2000 Feb 4;275(5):3100-6.

43.

Transforming growth factor-beta1 inhibits rat prolactin promoter activity in GH4 neuroendocrine cells.

Farrow KN, Gutierrez-Hartmann A.

DNA Cell Biol. 1999 Nov;18(11):863-73.

PMID:
10595400
45.

Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway.

Wasylyk B, Hagman J, Gutierrez-Hartmann A.

Trends Biochem Sci. 1998 Jun;23(6):213-6. Review.

PMID:
9644975
46.
47.

Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase.

Jensen DR, Schlaepfer IR, Morin CL, Pennington DS, Marcell T, Ammon SM, Gutierrez-Hartmann A, Eckel RH.

Am J Physiol. 1997 Aug;273(2 Pt 2):R683-9.

PMID:
9277555
49.

Combination of osteoinductive bone proteins differentiates mesenchymal C3H/10T1/2 cells specifically to the cartilage lineage.

Atkinson BL, Fantle KS, Benedict JJ, Huffer WE, Gutierrez-Hartmann A.

J Cell Biochem. 1997 Jun 1;65(3):325-39.

PMID:
9138089
50.

Lipopolysaccharide and Raf-1 kinase regulate secretory interleukin-1 receptor antagonist gene expression by mutually antagonistic mechanisms.

Guthridge CJ, Eidlen D, Arend WP, Gutierrez-Hartmann A, Smith MF Jr.

Mol Cell Biol. 1997 Mar;17(3):1118-28.

Supplemental Content

Loading ...
Support Center